Resource impact statement
Resource impact statement
NICE has recommended the selective internal radiation therapy (SIRT) QuiremSpheres as an option for treating unresectable advanced hepatocellular carcinoma (HCC) in adults, only if it is:
- used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and
- the company provides QuiremSpheres according to the commercial arrangement.
We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 57.1 million people).
This is because the technology is a further treatment option and the overall cost of treatment will be similar for this patient group.
Clinical trial evidence for QuiremSpheres is limited. It has not been directly compared with SIR-Spheres and TheraSphere. But the results from an indirect comparison suggest that QuiremSpheres is as effective as SIR-Spheres and TheraSphere. Additionally, the administration procedures are assumed to be the same, and there is no anticipated capacity impact.
No resource impact template has been provided with this statement because the overall cost of treatment is expected to be similar, and we do not anticipate any impact on capacity. However, if you require a template, please do not hesitate to contact us at nice@nice.org.uk.
The company has a commercial arrangement. This makes QuiremSpheres available to the NHS with a discount. The size of the discount is commercial in confidence.
This technology is for people with unresectable advanced hepatocellular carcinoma and is commissioned by NHS England. Providers are NHS hospital trusts.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
This page was last updated: